174 related articles for article (PubMed ID: 34541612)
1. Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial.
Öcal O; Rössler D; Gasbarrini A; Berg T; Klümpen HJ; Bargellini I; Peynircioglu B; van Delden O; Schulz C; Schütte K; Iezzi R; Pech M; Malfertheiner P; Sangro B; Ricke J; Seidensticker M
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2487-2496. PubMed ID: 34541612
[TBL] [Abstract][Full Text] [Related]
2. Correlation of liver enhancement in gadoxetic acid-enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial.
Öcal O; Peynircioglu B; Loewe C; van Delden O; Vandecaveye V; Gebauer B; Zech CJ; Sengel C; Bargellini I; Iezzi R; Benito A; Schütte K; Gasbarrini A; Seidensticker R; Wildgruber M; Pech M; Malfertheiner P; Ricke J; Seidensticker M
Eur Radiol; 2022 Feb; 32(2):1320-1329. PubMed ID: 34467453
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma.
Öcal O; Ingrisch M; Ümütlü MR; Peynircioglu B; Loewe C; van Delden O; Vandecaveye V; Gebauer B; Zech CJ; Sengel C; Bargellini I; Iezzi R; Benito A; Pech M; Malfertheiner P; Ricke J; Seidensticker M
Br J Cancer; 2022 Feb; 126(2):211-218. PubMed ID: 34686780
[TBL] [Abstract][Full Text] [Related]
4. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.
Rimola J; Forner A; Sapena V; Llarch N; Darnell A; Díaz A; García-Criado A; Bianchi L; Vilana R; Díaz-González Á; Ayuso C; Bruix J; Reig M
Eur Radiol; 2020 Jan; 30(1):186-194. PubMed ID: 31372783
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of baseline MRI features in patients treated with thermal ablation for hepatocellular carcinoma.
Öcal O; Schütte K; Malfertheiner P; Berg T; Loewe C; Klümpen HJ; Zech CJ; van Delden O; Ümütlü MR; Deniz S; Khaled NB; De Toni EN; Hoang TPT; Seidensticker R; Aghdassi A; Pech M; Ricke J; Seidensticker M
Eur J Radiol; 2023 Nov; 168():111120. PubMed ID: 37806190
[TBL] [Abstract][Full Text] [Related]
6. Prediction of sorafenib treatment-related gene expression for hepatocellular carcinoma: preoperative MRI and histopathological correlation.
Dong Z; Huang K; Liao B; Cai H; Dong Y; Huang M; Zhou X; Jia Y; Xu L; Luo Y; Li ZP; Feng ST
Eur Radiol; 2019 May; 29(5):2272-2282. PubMed ID: 30547202
[TBL] [Abstract][Full Text] [Related]
7. Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma.
Ricke J; Schinner R; Seidensticker M; Gasbarrini A; van Delden OM; Amthauer H; Peynircioglu B; Bargellini I; Iezzi R; De Toni EN; Malfertheiner P; Pech M; Sangro B
J Hepatol; 2021 Dec; 75(6):1387-1396. PubMed ID: 34454995
[TBL] [Abstract][Full Text] [Related]
8. Gadoxetic acid-enhanced MR imaging for hepatocellular carcinoma: molecular and genetic background.
Kitao A; Matsui O; Yoneda N; Kozaka K; Kobayashi S; Koda W; Inoue D; Ogi T; Yoshida K; Gabata T
Eur Radiol; 2020 Jun; 30(6):3438-3447. PubMed ID: 32064560
[TBL] [Abstract][Full Text] [Related]
9. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
Lee MH; Kim SH; Park MJ; Park CK; Rhim H
AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
[TBL] [Abstract][Full Text] [Related]
10. A radiomics-based biomarker for cytokeratin 19 status of hepatocellular carcinoma with gadoxetic acid-enhanced MRI.
Wang W; Gu D; Wei J; Ding Y; Yang L; Zhu K; Luo R; Rao SX; Tian J; Zeng M
Eur Radiol; 2020 May; 30(5):3004-3014. PubMed ID: 32002645
[TBL] [Abstract][Full Text] [Related]
11. Gadoxetic Acid-Based MRI for Decision-Making in Hepatocellular Carcinoma Employing Perfusion Criteria Only-A Post Hoc Analysis from the SORAMIC Trial Diagnostic Cohort.
Seidensticker M; Steffen IG; Bargellini I; Berg T; Benito A; Gebauer B; Iezzi R; Loewe C; Karçaaltincaba M; Pech M; Sengel C; van Delden O; Vandecaveye V; Zech CJ; Ricke J
Curr Oncol; 2022 Jan; 29(2):565-577. PubMed ID: 35200551
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
[TBL] [Abstract][Full Text] [Related]
13. Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression.
Öcal O; Zech CJ; Fabritius MP; Loewe C; van Delden O; Vandecaveye V; Gebauer B; Berg T; Sengel C; Bargellini I; Iezzi R; Benito A; Pech M; Gasbarrini A; Sangro B; Malfertheiner P; Ricke J; Seidensticker M
Eur Radiol; 2023 Jan; 33(1):493-500. PubMed ID: 35881180
[TBL] [Abstract][Full Text] [Related]
14. Hepatobiliary phase images of gadoxetic acid-enhanced MRI may improve accuracy of predicting the size of hepatocellular carcinoma at pathology.
Dong SY; Yang YT; Wang WT; Zhu S; Sun W; Zeng MS; Rao SX
Acta Radiol; 2022 Jun; 63(6):734-742. PubMed ID: 33969700
[TBL] [Abstract][Full Text] [Related]
15. Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study.
Kim SS; Kim SH; Song KD; Choi SY; Heo NH
J Magn Reson Imaging; 2020 Jan; 51(1):70-80. PubMed ID: 31062483
[TBL] [Abstract][Full Text] [Related]
16. Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging.
Kim R; Lee JM; Shin CI; Lee ES; Yoon JH; Joo I; Kim SH; Hwang I; Han JK; Choi BI
Eur Radiol; 2016 Jun; 26(6):1808-17. PubMed ID: 26373763
[TBL] [Abstract][Full Text] [Related]
17. Differentiation Between Hepatocellular Carcinoma Showing Hyperintensity on the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI and Focal Nodular Hyperplasia by CT and MRI.
Kitao A; Matsui O; Yoneda N; Kita R; Kozaka K; Kobayashi S; Gabata T
AJR Am J Roentgenol; 2018 Aug; 211(2):347-357. PubMed ID: 29708786
[TBL] [Abstract][Full Text] [Related]
18. Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial.
Öcal O; Schütte K; Kupčinskas J; Morkunas E; Jurkeviciute G; de Toni EN; Ben Khaled N; Berg T; Malfertheiner P; Klümpen HJ; Sengel C; Basu B; Valle JW; Benckert J; Gasbarrini A; Palmer D; Seidensticker R; Wildgruber M; Sangro B; Pech M; Ricke J; Seidensticker M
J Cancer Res Clin Oncol; 2022 Feb; 148(2):475-485. PubMed ID: 33855585
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival.
Kim HD; Lim YS; Han S; An J; Kim GA; Kim SY; Lee SJ; Won HJ; Byun JH
Gastroenterology; 2015 Jun; 148(7):1371-82. PubMed ID: 25733098
[TBL] [Abstract][Full Text] [Related]
20. Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients.
Phongkitkarun S; Limsamutpetch K; Tannaphai P; Jatchavala J
World J Gastroenterol; 2013 Dec; 19(45):8357-65. PubMed ID: 24363528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
